Sustained GLP-1 receptor agonist therapy is linked to greater improvements in A1c levels than DPP-4 inhibitor therapy in patients with type 2 diabetes, a Danish real-world analysis shows.

The initiation of GLP-1 agonists was associated with a lower risk for Alzheimer’s disease and related dementias than the initiation of DPP-4 inhibitors in patients with diabetes undergoing ...

GLP-1 drugs show a potential link to reduced epilepsy risk in people with type 2 diabetes. People taking GLP-1 drugs were 16% less likely to develop epilepsy than those on DPP-4 inhibitors.

Risk of recurrent major adverse limb events was lower in diabetes patients taking GLP-1 agents compared with DPP-4 inhibitors. Reduction of limb events was most significant for major amputations, ...

GLP-1 RAs show greater cardiovascular benefits in type 2 diabetes patients with BMI ≥25 compared to DPP-4 inhibitors. Kidney protection from GLP-1 RAs remains consistent across all BMI categories. The ...

Those prescribed a GLP-1 RA had a significantly increased risk for new chronic cough compared with those prescribed any non-GLP-1 RA second-line medication, DPP-4 inhibitor, or sulfonylurea in a ...

GLP-1RA use improves major cardiovascular and kidney outcomes among patients with systemic lupus erythematosus and lupus nephritis. Use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) is ...

Taking GLP-1 medications like Ozempic is linked to a smaller risk of developing epilepsy than taking DPP-4 inhibitors. The corresponding study was published in Neurology. "Additional randomized, ...

GLP-1 RA use was associated with significantly lower epilepsy risk, with protective associations seen at 1, 3, and 5 years. (HealthDay News) — For adults with type 2 diabetes mellitus (T2DM), glucagon ...